BMRA Biomerica, Inc.
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.
Company profile
Ticker
BMRA
Exchange
Website
CEO
Zackary S. Irani
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
IRS number
952645573
BMRA stock data
()
Calendar
14 Jan 20
27 Jan 20
31 May 20
News
Company financial data Financial data
| Quarter (USD) | Nov 19 | Aug 19 | May 19 | Feb 19 | |
|---|---|---|---|---|---|
| Revenue | 1.6M | 1.19M | 1.17M | 1.26M | |
| Net income | -485.26K | -506.3K | -785.33K | -678.75K | |
| Diluted EPS | -0.05 | -0.05 | -0.08 | -0.07 | |
| Net profit margin | -30.40% | -42.39% | -67.36% | -53.82% | |
| Operating income | -489.74K | -509.56K | -764.82K | -707.25K | |
| Net change in cash | 43.44K | 120.77K | -231.15K | -206.98K | |
| Cash on hand | 850.99K | 807.55K | 686.79K | 917.94K | |
| Cost of revenue | 1.13M | 827.11K | 985.05K | 895.24K |
| Annual (USD) | May 19 | May 18 | May 17 | May 16 | |
|---|---|---|---|---|---|
| Revenue | 5.2M | 5.56M | 5.79M | 5.14M | |
| Net income | -2.39M | -1.47M | -908.56K | -1.5M | |
| Diluted EPS | -0.26 | -0.17 | -0.11 | -0.2 | |
| Net profit margin | -46.01% | -26.34% | -15.69% | -29.18% | |
| Operating income | -2.41M | -1.48M | -954.63K | -826.95K | |
| Net change in cash | -518.12K | -20.56K | -663.46K | 800.62K | |
| Cash on hand | 686.79K | 1.2M | 1.23M | 1.89M | |
| Cost of revenue | 3.91M | 3.81M | 3.77M | 3.62M |
Financial data from Biomerica earnings reports
Institutional ownership Q3 2019
2.4% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 11 |
| Opened positions | 2 |
| Closed positions | 4 |
| Increased positions | 2 |
| Reduced positions | 1 |
13F shares |
Current |
|---|---|
| Total value | 752K |
| Total shares | 231.79K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | NaN |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 126.22K | $410K |
| Perritt Capital Management | 65K | $211K |
| Heritage Investors Management | 15.55K | $51K |
| Bard Associates | 10K | $33K |
| WFC Wells Fargo & Co. | 6.5K | $21K |
| BAC Bank of America | 3.83K | $12K |
| DB Deutsche Bank | 2.33K | $7K |
| Victory Capital Management | 1.34K | $4K |
| LTS Ladenburg Thalmann Financial Services | 1K | $3K |
| RY Royal Bank of Canada | 16 | $0 |
Financial report summary
?Management Discussion
- Consolidated net sales for Biomerica were $1,596,408 for the three months ended November 30, 2019 as compared to $1,500,791 for the same period in the previous year. This represents an increase of $95,617 or 6.4%. For the six-month period ended November 30, 2019 as compared to 2018, net sales were $2,790,823 as compared to $2,773,661. This represents an increase of $17,162 or 0.6%. The increase for the three and six-month periods was primarily due to increased sales to Asia and several orders to the Middle East.
- For the three months ended November 30, 2019 as compared to November 30, 2018, cost of sales decreased as a percentage of sales from 72.8% of sales, or $1,092,731, to 70.6% of sales, or $1,127,536. For the six months ended November 30, 2019 as compared to 2018, cost of sales decreased as a percentage of sales from 73.1% of sales, or $2,028,378 to 70.0% of sales, or $1,954,647. Decreases to cost of sales as a percentage of sales for the three and six months were due to lower scrap as well as fixed costs in relationship to higher sales.
- For the three months ended November 30, 2019 compared to 2018, selling, general and administrative expenses increased by $41,169, or 8.0%. For the six-month period ended November 30, 2019 as compared to 2018, these expenses increased by $148,138, or 16.1%. The increase in the three and six-month period was primarily due to increased wages primarily due to increased wages classified as administrative and the addition of a sales manager in Europe.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
addressable, constant, create, deposit, deposited, disease, earned, East, inflammatory, Middle, Multiple, strategic
Financial reports
10-Q
2020 Q2
Quarterly report
14 Jan 20
10-Q
2020 Q1
Quarterly report
15 Oct 19
10-K
2019 FY
Annual report
29 Aug 19
10-Q
2019 Q3
Quarterly report
15 Apr 19
10-Q
2019 Q2
Quarterly report
14 Jan 19
10-Q
2019 Q1
Quarterly report
15 Oct 18
10-K
2018 FY
Annual report
29 Aug 18
10-Q
2018 Q3
Quarterly report
16 Apr 18
10-Q/A
2018 Q2
Quarterly report (amended)
17 Jan 18
10-Q
2018 Q2
Quarterly report
16 Jan 18
Current reports
8-K
Regulation FD Disclosure
9 Jan 20
8-K
Submission of Matters to a Vote of Security Holders
13 Dec 19
8-K
Other Events
4 Sep 19
8-K
Other Events
5 Jun 19
8-K
Other Events
9 Apr 19
8-K
Departure of Directors or Certain Officers
21 Mar 19
8-K
Submission of Matters to a Vote of Security Holders
14 Dec 18
8-K
Regulation FD Disclosure
28 Sep 18
8-K
Other Events
27 Aug 18
8-K
Other Events
8 Mar 18
Registration and prospectus
S-8
Registration of securities for employees
10 May 18
424B5
Prospectus supplement for primary offering
4 Dec 17
S-3
Shelf registration
30 Jun 17
8-A12B
Registration of securities on exchange
23 Aug 16
S-8
Registration of securities for employees
22 May 15
S-8
Registration of securities for employees
9 Feb 12
S-8
Registration of securities for employees
30 May 07
REGDEX
Notice of sale of securities
12 Jun 06
REGDEX
Notice of sale of securities
7 Jul 03
RW
Registration withdrawal request
27 Sep 02
Proxies
DEF 14A
Definitive proxy
24 Sep 19
DEF 14A
Definitive proxy
28 Sep 18
DEF 14A
Definitive proxy
28 Sep 17
DEF 14A
Definitive proxy
28 Sep 16
DEF 14A
Definitive proxy
28 Sep 15
DEF 14A
Definitive proxy
29 Sep 14
DEF 14A
Definitive proxy
30 Sep 13
DEF 14A
Definitive proxy
28 Sep 12
DEF 14A
Definitive proxy
28 Sep 11
DEF 14A
Definitive proxy
29 Sep 10
Other
EFFECT
Notice of effectiveness
20 Jul 17
CORRESP
Correspondence with SEC
18 Jul 17
UPLOAD
Letter from SEC
6 Jul 17
UPLOAD
Letter from SEC
17 Mar 09
CORRESP
Correspondence with SEC
16 Mar 09
CORRESP
Correspondence with SEC
4 Mar 09
UPLOAD
Letter from SEC
4 Mar 09
UPLOAD
Letter from SEC
20 Feb 09
UPLOAD
Letter from SEC
14 Apr 05
CORRESP
Correspondence with SEC
7 Apr 05